

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2013 Army **DATE:** February 2012

APPROPRIATION/BUDGET ACTIVITY				R-1 ITEM NOMENCLATURE							
2040: <i>Research, Development, Test & Evaluation, Army</i> BA 5: <i>Development & Demonstration (SDD)</i>				PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>							
COST (\$ in Millions)	FY 2011	FY 2012	FY 2013 Base	FY 2013 OCO	FY 2013 Total	FY 2014	FY 2015	FY 2016	FY 2017	Cost To Complete	Total Cost
Total Program Element	33.262	27.132	43.395	-	43.395	46.634	47.252	48.312	49.126	Continuing	Continuing
812: <i>MIL HIV VAC&DRUG DEV</i>	4.297	3.860	3.232	-	3.232	4.292	4.444	4.539	4.616	Continuing	Continuing
832: <i>Field Medical Systems Engineering Development</i>	17.159	14.793	23.971	-	23.971	27.469	27.528	28.452	28.932	Continuing	Continuing
849: <i>INFEC DIS DRUG/VACC ED</i>	11.806	8.479	13.771	-	13.771	14.873	15.280	15.321	15.578	Continuing	Continuing
VS8: <i>MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - END DEV</i>	-	-	2.421	-	2.421	-	-	-	-	Continuing	Continuing

A. Mission Description and Budget Item Justification

This program element (PE) funds advanced development of medical materiel within the System Demonstration and Low Rate Initial Production portions of the acquisition life cycle using 6.5 funding. It supports products successfully developed in the Systems Integration portion of the Systems Development and Demonstration phases through completion of the Milestone C Decision Review. Commercially-off-the-shelf (COTS) medical products are also tested and evaluated for military use, when available. This PE primarily includes pivotal (conclusive) human clinical trials necessary for licensure by the Food and Drug Administration.

(PROJ 812) project funds military relevant human immunodeficiency virus (HIV) medical countermeasures. These funds provide for engineering and manufacturing development of candidate vaccines and drugs to permit large-scale field testing. Development focused on military unique needs effecting manning, mobilization, and deployment. Products from this project will normally transition to DoD Health Programs or OPA Funds.

(PROJ 832) this project funds the engineering and manufacturing development of medical products for enhanced combat casualty care and follow-on care, including rehabilitation. Mature commercial-off-the-shelf (COTS) medical products are also evaluated for military use. Consideration will also be given to reduce the medical sustainment footprint through smaller weight and cube volume, or equipment independence from supporting materiel. Products from this project will normally transition to OPA Funds.

(PROJ 849) funds development of candidate medical countermeasures for military relevant infectious diseases. These products fall between four major areas: vaccines, drugs, diagnostic kits/devices, and insect control measures to limit exposure and disease transmission. FDA approval is a mandatory obligation for all military products placed into the hands of medical providers or service members for human use. Products from this project will normally transition to DoD Health Programs or OPA funds.

(PROJ VS8) program receives products that transition from VS7 and funds effort to complete research and development for the MEDEVAC Mission Essential Packages (MEPs) to support 256 Medical Evacuation legacy helicopters. The force design will increase the number of air frames in the force from 12 to 15 aircraft for 37 MEDEVAC companies to better meet operation needs.

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2013 Army	DATE: February 2012
---	----------------------------

APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 5: <i>Development & Demonstration (SDD)</i>	R-1 ITEM NOMENCLATURE PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>
---	---

This program is managed by U.S. Army Medical Materiel Development Activity (USAMMDA) and U.S. Army Medical Materiel Agency (USAMMA) of the US Army Medical Research and Materiel Command.

B. Program Change Summary (\$ in Millions)	<u>FY 2011</u>	<u>FY 2012</u>	<u>FY 2013 Base</u>	<u>FY 2013 OCO</u>	<u>FY 2013 Total</u>
Previous President's Budget	34.474	27.160	41.872	-	41.872
Current President's Budget	33.262	27.132	43.395	-	43.395
Total Adjustments	-1.212	-0.028	1.523	-	1.523
• Congressional General Reductions	-	-			
• Congressional Directed Reductions	-	-			
• Congressional Rescissions	-	-			
• Congressional Adds	-	-			
• Congressional Directed Transfers	-	-			
• Reprogrammings	-	-			
• SBIR/STTR Transfer	-0.998	-			
• Adjustments to Budget Years	-	-	1.523	-	1.523
• Other Adjustments 1	-0.214	-0.028	-	-	-

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2013 Army								DATE: February 2012			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 5: Development & Demonstration (SDD)				R-1 ITEM NOMENCLATURE PE 0604807A: Medical Materiel/Medical Biological Defense Equipment - Eng Dev				PROJECT 812: MIL HIV VAC&DRUG DEV			
COST (\$ in Millions)	FY 2011	FY 2012	FY 2013 Base	FY 2013 OCO	FY 2013 Total	FY 2014	FY 2015	FY 2016	FY 2017	Cost To Complete	Total Cost
812: MIL HIV VAC&DRUG DEV	4.297	3.860	3.232	-	3.232	4.292	4.444	4.539	4.616	Continuing	Continuing
Quantity of RDT&E Articles											
A. Mission Description and Budget Item Justification											
This project funds militarily relevant human immunodeficiency virus (HIV) medical countermeasures. These funds provide for engineering and manufacturing development of candidate vaccines and drugs to permit large-scale field testing. Development is focused on militarily unique needs effecting manning, mobilization, and deployment.											
The major contractor is The Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD. Research efforts are coordinated with the National Institutes of Health.											
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)								FY 2011	FY 2012	FY 2013	
Title: Military HIV Vaccine and Drug Development <div>Articles:</div> Description: This project provides funds for engineering and manufacturing development of candidate vaccines and drugs to permit large-scale field testing of vaccines for medical countermeasures to HIV FY 2011 Accomplishments: Finalized and submitted results to the Food and Drug Administration (FDA) from the expanded safety/efficacy trial in Thailand, updated/revised the clinical development plan, and continued to follow up clinical trial for HIV positive for viral load. FY 2012 Plans: Perform three inter-related studies to enhance our understanding of how the vaccine strategy used in the 2009 safety/efficacy trial caused vaccine recipients to be protected from infection, including intense laboratory studies using samples from the trial, and commencement of two small clinical vaccine trials to generate data and samples to define what vaccine responses to try to generate for next increment studies. FY 2013 Plans: Will refine vaccine administration schedule as well as clinical trial design based on data from previous clinical trials. Will adjust plan for increment 1 future efficacy trial planned to begin in late 2014.								4.297	3.860	3.232	
								0	0		
Accomplishments/Planned Programs Subtotals								4.297	3.860	3.232	

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2013 Army		DATE: February 2012
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 5: <i>Development & Demonstration (SDD)</i>	R-1 ITEM NOMENCLATURE PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>	PROJECT 812: <i>MIL HIV VAC&DRUG DEV</i>
C. Other Program Funding Summary (\$ in Millions) N/A		
D. Acquisition Strategy Test and evaluate commercially developed vaccine candidates in government-managed trials.		
E. Performance Metrics Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.		

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2013 Army										DATE: February 2012			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 5: Development & Demonstration (SDD)				R-1 ITEM NOMENCLATURE PE 0604807A: Medical Materiel/Medical Biological Defense Equipment - Eng Dev				PROJECT 812: MIL HIV VAC&DRUG DEV					
Management Services (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	Various	Various:Various	1.124	0.215		0.299		-		0.299	Continuing	Continuing	0.000
Subtotal			1.124	0.215		0.299		-		0.299			0.000
Product Development (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Product Development	Various	Henry M. Jackson Foundation,:Various	27.742	2.655		2.145		-		2.145	Continuing	Continuing	Continuing
Subtotal			27.742	2.655		2.145		-		2.145			
Support (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	Various	Various:Various	0.580	0.046		0.031		-		0.031	Continuing	Continuing	0.000
Subtotal			0.580	0.046		0.031		-		0.031			0.000
Test and Evaluation (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Product Development	Various	Henry M. Jackson Foundation,:Various	23.446	0.944		0.757		-		0.757	Continuing	Continuing	Continuing
Subtotal			23.446	0.944		0.757		-		0.757			

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2013 Army								DATE: February 2012			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 5: Development & Demonstration (SDD)				R-1 ITEM NOMENCLATURE PE 0604807A: Medical Materiel/Medical Biological Defense Equipment - Eng Dev				PROJECT 812: MIL HIV VAC&DRUG DEV			
	Total Prior Years Cost	FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals	52.892	3.860		3.232		-		3.232			

Remarks

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2013 Army															DATE: February 2012														
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 5: <i>Development & Demonstration (SDD)</i>										R-1 ITEM NOMENCLATURE PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>										PROJECT 812: <i>MIL HIV VAC&DRUG DEV</i>									

	FY 2011				FY 2012				FY 2013				FY 2014				FY 2015				FY 2016				FY 2017			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
Phase 2 study of Vaccine candidates																												
Initiate Phase 3 Study of Vaccine candidates																												
Increment 1 Efficacy Trial																												

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2013 Army			DATE: February 2012
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 5: <i>Development & Demonstration (SDD)</i>	R-1 ITEM NOMENCLATURE PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>	PROJECT 812: <i>MIL HIV VAC&DRUG DEV</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
Phase 2 study of Vaccine candidates	1	2014	2	2014
Initiate Phase 3 Study of Vaccine candidates	1	2015	1	2015
Increment 1 Efficacy Trial	4	2014	2	2015

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2013 Army									DATE: February 2012		
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 5: Development & Demonstration (SDD)				R-1 ITEM NOMENCLATURE PE 0604807A: Medical Materiel/Medical Biological Defense Equipment - Eng Dev				PROJECT 832: Field Medical Systems Engineering Development			
COST (\$ in Millions)	FY 2011	FY 2012	FY 2013 Base	FY 2013 OCO	FY 2013 Total	FY 2014	FY 2015	FY 2016	FY 2017	Cost To Complete	Total Cost
832: Field Medical Systems Engineering Development	17.159	14.793	23.971	-	23.971	27.469	27.528	28.452	28.932	Continuing	Continuing
Quantity of RDT&E Articles											

A. Mission Description and Budget Item Justification

This project funds the engineering and manufacturing development of medical products for enhanced combat casualty care and follow-on care, including rehabilitation. This project funds pivotal (conclusive) human clinical trials or mechanical engineering evaluations for efficacy of devices or biologics (products derived from living organisms) to fulfill unique military requirements. Mature commercial-off-the-shelf (COTS) medical products are also evaluated for military use. Consideration will also be given to reducing the medical sustainment footprint through smaller weight and cube volume, or equipment independence from supporting materiel. This work is frequently completed through a laboratory/contractor team with the contractor obtaining the U.S. Food and Drug Administration (FDA) licensure for sale of the product.

Major contractors/intra-governmental agencies include: IGR Enterprises, Inc.; Army Medical Department Board Test Center; SeQual Technologies, Inc.; Enginivity, Inc.; Ultrasound Diagnostics, Inc.; HemCon Medical Technologies, Inc.; Cerdak Ltd; Hemerus Medical, LLC; Fast Track Drugs & Biologics, LLC; Integrated Medical Systems, Inc; the National Institutes of Health National Heart, Lung and Blood Institute (NHLBI), and the U.S. Army Aeromedical Research Laboratory Walter Reed Army Institute of Research (WRAIR) and Institute of Surgical Research (ISR) for user evaluation. Other military agencies include Program Executive Office (PEO) Soldier, PEO Combat Service Support (CSS), and Naval Undersea Warfare Center.

B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)

	FY 2011	FY 2012	FY 2013
Title: Medical Materiel/Medical Biological Defense Equipment- Engineering Development FY 2010 and 2011	17.159	-	-
Articles:	0		
Description: This project funds in FY 2010 and 2011 the engineering and manufacturing development of medical products for enhanced combat casualty care and follow-on care, including rehabilitation.			
FY 2011 Accomplishments: In FY 2011, Freeze-dried Plasma: start enrollment in the multi-center limited human safety/efficacy clinical trial and evaluate stability profile of the product. Red Blood Cell Extended Life Program: complete the human safety/efficacy study, conduct data analysis, and prepare and submit report to the FDA. Platelet Derived Hemostatic Agent (PDHA): transition from project 836 to begin enrollment/follow-up in the human safety/efficacy trial. Intranasal Ketamine (low dose pain management via nasal spray): transition from project 836 and conduct pre-clinical trial activities for human drug use in aeromedical evacuation and burn patients. Hypertonic Saline Dextran (treatment of shock due to blood loss): support human expanded safety/efficacy trial for treatment of shock. Continue market analysis and surveys for candidate resuscitative fluids for treatment of shock. Enhanced SAVe: Conduct clinical user evaluation and operational testing. Remote Diagnostic Access: Conduct Prototype field testing and refinement for			

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2013 Army			DATE: February 2012		
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 5: <i>Development & Demonstration (SDD)</i>		R-1 ITEM NOMENCLATURE PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>		PROJECT 832: <i>Field Medical Systems Engineering Development</i>	
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)			FY 2011	FY 2012	FY 2013
MOC Sensor Modul Development phase of this device. Treatment Table for PM, HBCT Medical Mission Package for Treatment Variants: Transition from Project 836. Transition to production for use on PM, HBCT Treatment Variant. Refrigerator for PM, HBCT for Medical Mission Package for Treatment Variant: Transition from Project 836. Conduct environmental and operational testing. Shelter for PM, HBCT Treatment Variant: Transition from Project 836. Evaluate alternatives in operational setting. Shock and Vibration Isolation System for Patient Litters in Ground and Air Medical Evacuation Vehicles: Transition from Project 836. Conduct Shock and Vibration Isolation System for patient litters - air worthiness and ground vehicle testing. One-handed tourniquet update: Conduct study to update medical set and down select product. Passive Cold Chain Capability for Temperature Sensitive Medical Materiel: Transition from Project 836. Conduct environmental testing and user testing.					
Title: Field Medical Systems Engineering Development FY 2012 PM Medical Devices Articles: Description: This project funds in FY 2012 the engineering and manufacturing development of medical products for enhanced combat casualty care managed by PM Medical Devices. FY 2012 Plans: The Burn Resuscitation Decision Device: Will conduct final environmental, operational and clinical testing on device for MS C submission. Wireless Medical Monitoring will transition from Congressional Special Interest (CSI) project to an Army Core funded project and will undergo a Milestone C review as well as prototype field testing. Plasma Knife: Will transition from 836 6.4 funding line into 832 6.5 funding line. Will finalize results of clinical and operational testing. Will also identify and address all refinements and undergo Milestone C review in 4Q. FY 2013 Plans: Enhanced SAVE: No further R&D funding required as this is now a COTS product. The Burn Resuscitation Decision Device: Preparing documentation for CPD and MS B/C. No further R&D required as this product will transition to procurement in FY 2013. MS B/C expected 2Q FY 2013. Total Intravenous Anesthesia (TIVA): This product is transitioning to tech watch in FY 2012. Wireless Medical Monitoring: no requirement and no RDTE planned. Plasma Knife: No further R&D funding required as this is now a COTS product. Noise-Immune Stethoscope: Will finalize and conduct a MS C review in FY 2012; no RDTE efforts for FY 2013. Oxygen Generator (15 LPM) System: 15LPM draft CDD completed and a request for proposals (RFP) award is expected in March 2012. Will continue development with a target to field in FY 2015. Replacement for the M-138 Steam Sterilizer: FY 2013 funding planned for testing of the device. Will begin design and development of system in FY 2012 and continue development through FY 2013. One-Handed Tourniquet update: No RDTE efforts in FY 2012 or FY 2013.			-	6.019 0	0.200
Title: Field Medical Systems Engineering Development FY 2012 PM Pharmaceuticals Articles:			-	5.034 0	17.599

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2013 Army			DATE: February 2012		
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 5: <i>Development & Demonstration (SDD)</i>		R-1 ITEM NOMENCLATURE PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>		PROJECT 832: <i>Field Medical Systems Engineering Development</i>	
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)			FY 2011	FY 2012	FY 2013
Description: Funding is provided for engineering and manufacturing development of medical products managed by PM Pharmaceuticals for enhanced combat casualty care and follow-on care, including rehabilitation. FY 2012 Plans: Freeze-Dried Plasma: Begin enrollment in a multi-center limited human safety/efficacy clinical trial; will Begin improvement of manufacturing & laboratory capabilities to meet Food and Drug Administration requirements; and will evaluate stability profile of the product. Cryopreserved Platelets (CPP) (formerly Platelet Derived Hemostatic Agent (PDHA): Continue enrollment/follow-up in a human safety/efficacy clinical trial. FY 2013 Plans: Blood Pathogen Reduction/Inactivation transitioned to advanced development in FY 2012, transitioning from Army to be funded with Defense Health Program RDT&E funding; transitioned to Freeze-dried Plasma program to maintain current schedule and avoid delays. Freeze-Dried Plasma: Finalize Phase 3 test plan and protocols, recruit test sites for Phase 3 Pivotal clinical trial, and continue development of commercially sustainable current Good Manufacturing Practices compliant manufacturing capability. Accelerated fielding of a FDA-approved Freeze-Dried Plasma was validated in the June 2011 Army Surgeon General's Report by the Blast Injury Task Force. Cryopreserved Platelets: Continue validation of current Good Manufacturing Practices manufacturing processes in support of U.S. Food and Drug Administration licensure. Develop Phase 3 clinical testing network and protocols if Phase 3 Pivotal clinical trial is required by the U.S. Food and Drug Administration.					
Title: Field Medical Systems Engineering Development FY 2012 PM Integrated Clinical Systems (ICS) Articles: Description: This project funds in FY 2012 the engineering and manufacturing development of medical products managed by PM ICS for enhanced combat casualty care and follow-on care, including rehabilitation. FY 2012 Plans: Will conduct final testing of Phase IV of Remote Access Device (RDA). Will Develop a universal security compliant access portal to serve as a standardized compliance wrapper for all vendors, medical technology, and even IT management products that may traverse between the .com and .mil networks. The Milestone Decision Authority (MDA) has scheduled an in process review for the RDA project in March 2011 .			-	0.737 0	-
Title: Field Medical Systems Engineering Development FY 2012 PM Medical Support Systems Articles: Description: This project funds in FY 12 the engineering and manufacturing development of medical products managed by PM Medical Support Systems for enhanced combat casualty care and follow-on care, including rehabilitation.			-	3.003 0	6.172

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2013 Army		DATE: February 2012	
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 5: <i>Development & Demonstration (SDD)</i>	R-1 ITEM NOMENCLATURE PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>	PROJECT 832: <i>Field Medical Systems Engineering Development</i>	
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)		FY 2011	FY 2012
<p><i>FY 2012 Plans:</i> Collaborate with PM HBCT on medical equipment for the future treatment vehicle variant. Test and evaluate the shock and litter isolation system for potential addition to Ground Ambulance and Air Ambulance Medical Equipment Sets (MES). Transition to Force Provider by fielding a Force Provider CSH. Fully test the new 2-sided ISO shelter under the Joint shelter Program and finalize acquisition strategy in coordination with Program Manager's Force Provider program. Continue to develop Medical Evacuation Vehicles in coordination with Program Executive Office Combat Service Support vehicle developers.</p> <p><i>FY 2013 Plans:</i> Will transition from 836 and collaborate with PM HBCT on final integration/operational testing of the treatment table and blood refrigerator in the future treatment vehicle variant. As part of the medical equipment sets, will transition cold chain technology, trauma tiered medical bag, water/waste water management system, and quad fold litter from 836 and complete operational evaluation. Will continue modernization of medical equipment sets for preventive medicine, air and ground medical evacuation, and fresh water/waste water combat support hospital support. Will transition ISO panel from 836 and complete operational testing. Will transition from 836 and complete final operational evaluation of Force Provider CSH. Will complete operational/technical testing of Future Medical Shelter System (hard-wall 1-sided and 2-sided shelters) for a materiel procurement decision. Will continue collaboration with PEO Combat Service Support on finalization of MRAP medical vehicle evacuation platforms including a redesign of the Casualty Evacuation (CASEVAC) medical equipment set.</p>			
Accomplishments/Planned Programs Subtotals		17.159	14.793
C. Other Program Funding Summary (\$ in Millions)			
N/A			
D. Acquisition Strategy			
Develop in-house or industrial prototypes in government-managed programs to meet military and regulatory requirements for production and fielding.			
E. Performance Metrics			
Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.			

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2013 Army										DATE: February 2012			
APPROPRIATION/BUDGET ACTIVITY				R-1 ITEM NOMENCLATURE				PROJECT					
2040: Research, Development, Test & Evaluation, Army BA 5: Development & Demonstration (SDD)				PE 0604807A: Medical Materiel/Medical Biological Defense Equipment - Eng Dev				832: Field Medical Systems Engineering Development					
Management Services (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1Million individually	Various	Various:Various	22.060	0.418		2.577		-		2.577	Continuing	Continuing	Continuing
Subtotal			22.060	0.418		2.577		-		2.577			
Product Development (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Freeze-dried Human Plasma	Various	HemCon Medical Technologies, Inc.;Tigard OR	17.525	5.796		6.000		-		6.000	Continuing	Continuing	Continuing
Hypertonic Saline Dextran	Various	National Institutes of Health, National Heart, Lung and Blood Institute (NHLBI):Various	15.100	-		-		-		-	Continuing	Continuing	Continuing
Extended Life Red Blood Cell Product	Various	Hemerus Medical, LLC,:Various	3.140	-		-		-		-	Continuing	Continuing	Continuing
No product/contract costs greater than \$1M individually	Various	Various:Various	3.260	-		0.250		-		0.250	Continuing	Continuing	Continuing
Cryopreserved Platelets	Various	Multiple DoD activities and Dartmouth Hitchcock Med Ctr:North Potomac, MD	-	7.757		9.108		-		9.108	Continuing	Continuing	Continuing
Subtotal			39.025	13.553		15.358		-		15.358			

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2013 Army										DATE: February 2012			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 5: Development & Demonstration (SDD)				R-1 ITEM NOMENCLATURE PE 0604807A: Medical Materiel/Medical Biological Defense Equipment - Eng Dev				PROJECT 832: Field Medical Systems Engineering Development					
Support (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Regulatory Support	Various	Clinical Research Management, Inc.,: Various	5.557	-		-		-		-	Continuing	Continuing	Continuing
No product/contract costs greater than \$1 Million individually	Various	Various: Various	4.328	0.418		1.108		-		1.108	Continuing	Continuing	Continuing
Subtotal			9.885	0.418		1.108		-		1.108			
Test and Evaluation (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1 Million individually	Various	Various: Various	7.292	0.404		4.928		-		4.928	Continuing	Continuing	Continuing
Subtotal			7.292	0.404		4.928		-		4.928			
			Total Prior Years Cost	FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals			78.262	14.793		23.971		-		23.971			
Remarks													

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2013 Army																				DATE: February 2012																	
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 5: Development & Demonstration (SDD)										R-1 ITEM NOMENCLATURE PE 0604807A: Medical Materiel/Medical Biological Defense Equipment - Eng Dev										PROJECT 832: Field Medical Systems Engineering Development																	
										FY 2011				FY 2012				FY 2013				FY 2014				FY 2015				FY 2016				FY 2017			
										1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
Total Intravenous Anesthesia (TIVA) (MS-C)																																					
Burn Resuscitation Decision Device (MS-C)																																					
Wireless Medical Monitoring (MS-C)																																					
Plasma Knife (MS-C)																																					

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2013 Army		DATE: February 2012
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 5: <i>Development & Demonstration (SDD)</i>	R-1 ITEM NOMENCLATURE PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>	PROJECT 832: <i>Field Medical Systems Engineering Development</i>

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
Total Intravenous Anesthesia (TIVA) (MS-C)	1	2013	1	2013
Burn Resuscitation Decision Device (MS-C)	2	2012	2	2012
Wireless Medical Monitoring (MS-C)	4	2012	4	2012
Plasma Knife (MS-C)	2	2012	2	2012

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2013 Army								DATE: February 2012			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 5: Development & Demonstration (SDD)				R-1 ITEM NOMENCLATURE PE 0604807A: Medical Materiel/Medical Biological Defense Equipment - Eng Dev				PROJECT 849: INFEC DIS DRUG/VACC ED			
COST (\$ in Millions)	FY 2011	FY 2012	FY 2013 Base	FY 2013 OCO	FY 2013 Total	FY 2014	FY 2015	FY 2016	FY 2017	Cost To Complete	Total Cost
849: INFEC DIS DRUG/VACC ED	11.806	8.479	13.771	-	13.771	14.873	15.280	15.321	15.578	Continuing	Continuing
Quantity of RDT&E Articles											
A. Mission Description and Budget Item Justification											
This project funds development of candidate medical countermeasures for militarily relevant infectious diseases. These products fall within four major areas: vaccines, drugs, diagnostic kits/devices, and insect control measures to limit exposure and disease transmission. It funds research that supports conclusive human clinical trials for large-scale human efficacy testing, expanded human safety clinical trials, long-term animal studies, and related manufacturing tests. This work, which is jointly performed by military laboratories, civilian contracted pharmaceutical firms and foreign research partners, is directed toward the prevention of disease, early diagnosis, and speeding recovery once diagnosed. Medical products approved for human use must successfully complete a series of clinical trials that are required and regulated by the U.S. Food and Drug Administration (FDA). FDA approval is a mandatory obligation for all military products placed into the hands of medical providers or service members for human use. Development priority is based upon four major factors: (1) the extent of the disease within the Combatant Commands' theater of operations, (2) the clinical severity of the disease, (3) the technical maturity of the proposed solution, and (4) the affordability of the solution (development, production, and sustainment). Malaria, dysentery, hepatitis, and dengue diseases (a severe debilitating disease transmitted by mosquitoes), which are found in Africa Command, Central Command, European Command, Southern Command, and Pacific Command areas are at the top of the infectious diseases requirements list.											
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)								FY 2011	FY 2012	FY 2013	
Title: FY 2010 Malaria Drug/ Vaccine Engineering Development Articles: Description: This project funds development of candidate medical countermeasures for militarily relevant infectious diseases. FY 2011 Accomplishments: Conducted clinical trials, developmental testing, and reviews of malarial/antimalarial vaccines, drugs, diagnostics and insect repellents. For Tafenoquine, completed pre-trial activities for a large-scale safety/efficacy human clinical trial (treatment indication) in a malaria endemic country.								4.147	-	-	
								0			
Title: FY 2010 Infectious Disease Drug and Vaccine Engineering Development Articles: Description: FY 2010 funding for research and development efforts described below. FY 2011 Accomplishments: Analyzed the data for Topical Antileishmanial Cream, and prepared the final report on the Tunisia large scale human safety/ efficacy trial, continued pretrial activities for enrollment in the second large scale (> 300 subjects) human safety/efficacy trial in Central/South America. Analyzed the data and prepared the final report for the three small scale (<35 subjects) pharmacokinetic								7.659	8.479	13.771	
								0	0		

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2013 Army		DATE: February 2012	
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 5: <i>Development & Demonstration (SDD)</i>	R-1 ITEM NOMENCLATURE PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>	PROJECT 849: <i>INFEC DIS DRUG/VACC ED</i>	
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)		FY 2011	FY 2012
(drug metabolism) human trials in France, Peru and Panama. Continued a human treatment protocol in the U.S For Pentostam. Completed the study report for DTV vaccine on the expanded human safety and immunity trial in Puerto Rico and began the expanded safety and efficacy trial in children in Thailand. Continued maintenance of study blood specimens for Hepatitis E vaccine kept under cold storage and monitored industry partner's Hepatitis E vaccine development effort. FY 2012 Plans: Conduct Clinical trials, developmental testing, and reviews of malarial/antimalarial vaccines, drugs, diagnostics and insect repellents. Down-select from candidate anti-malaria drugs (e.g. Tafenoquine and other drugs) to prepare for clinical trial activities for a safety/efficacy human clinical trial (treatment indication) in a malaria endemic country. Conduct clinical trials, developmental testing, and appropriate reviews of grouped vaccines, drugs, and diagnostics (Leishmaniasis (a skin-based disease caused by a parasite and transmitted by sand flies), Dengue (a severe debilitating disease caused by a virus and transmitted by a mosquito), and other viral diseases: For Topical Antileishmanial Cream, begin the clinical study report on the Tunisia large scale human safety/efficacy trial, begin enrollment efforts in the second large scale (> 300 subjects) human safety/efficacy trial in Central/South America. For Dengue Tetravalent Vaccine (DTV), begin study close out activities for expanded safety and efficacy trial in children in Thailand; begin a new DTV large scale (> 300 subjects) human trial in Thailand and Philippines to expand safety data and demonstrate efficacy in children/adults. FY 2013 Plans: Review and analyze data from the on-going Adult Indication study begun in FY 2012 with industry partner Sanofi Pasteur and determine a Go/No Go Decision on continued product development for the Dengue Tetravalent Vaccine. Phase 3 clinical effectiveness studies are on-going with industry partner Sanofi Pasteur for the Dengue Tetravalent Vaccine, as well as Phase 3 studies for traveler/military indication. Complete preparation prior to initiating Phase 3 Pivotal clinical trial for Malaria Prophylaxis Drug. For Topical Antileishmanial Cream, complete Phase 2 safety and effectiveness New World clinical trial analysis and complete Phase 3 New World Pivotal clinical trial, and begin New World Treatment Protocol for Phase 3 site(s). The enteric JBAIDS assay transitions to advanced development and clinical trial planning begins. The Dengue Rapid Diagnostic Device (DRDD) (Hand Held Infectious Disease Diagnostics) transitions to advanced development and will be evaluated in a multi-site clinical performance study. Leishmania Rapid Diagnostic Device (LRDD) will continue the new world clinical trial started in FY 2012. The Leishmania Skin Test project will complete FDA approval and transition to procurement. The Antimalarial Drug, Artesunate Intravenous will transition from 808 and conduct MS C review.			
Accomplishments/Planned Programs Subtotals		11.806	8.479
C. Other Program Funding Summary (\$ in Millions) N/A		13.771	

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2013 Army		DATE: February 2012
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 5: <i>Development & Demonstration (SDD)</i>	R-1 ITEM NOMENCLATURE PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>	PROJECT 849: <i>INFEC DIS DRUG/VACC ED</i>
<p><u>D. Acquisition Strategy</u></p> <p>Test and evaluate in-house and commercially developed products in government-managed trials to meet FDA requirements and Environmental Protection Agency registration.</p> <p><u>E. Performance Metrics</u></p> <p>Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.</p>		

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2013 Army											DATE: February 2012		
APPROPRIATION/BUDGET ACTIVITY				R-1 ITEM NOMENCLATURE				PROJECT					
2040: Research, Development, Test & Evaluation, Army BA 5: Development & Demonstration (SDD)				PE 0604807A: Medical Materiel/Medical Biological Defense Equipment - Eng Dev				849: INFEC DIS DRUG/VACC ED					
Management Services (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	Various	Various:Various	12.558	1.931		2.172		-		2.172	Continuing	Continuing	Continuing
Subtotal			12.558	1.931		2.172		-		2.172			
Product Development (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	Various	Various:Various	21.423	3.171		4.034		-		4.034	Continuing	Continuing	Continuing
Topical Antileishmanial Drug	TBD	TBD:TBD	-	-		2.400		-		2.400	0.000	2.400	0.000
Subtotal			21.423	3.171		6.434		-		6.434			
Support (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	Various	Various:Various	10.951	0.992		2.620		-		2.620	Continuing	Continuing	Continuing
Subtotal			10.951	0.992		2.620		-		2.620			
Test and Evaluation (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	Various	Various:Various	31.778	2.385		2.545		-		2.545	Continuing	Continuing	Continuing
Subtotal			31.778	2.385		2.545		-		2.545			

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2013 Army								DATE: February 2012			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 5: Development & Demonstration (SDD)				R-1 ITEM NOMENCLATURE PE 0604807A: Medical Materiel/Medical Biological Defense Equipment - Eng Dev				PROJECT 849: INFEC DIS DRUG/VACC ED			
	Total Prior Years Cost	FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals	76.710	8.479		13.771		-		13.771			

Remarks

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2013 Army																DATE: February 2012												
APPROPRIATION/BUDGET ACTIVITY								R-1 ITEM NOMENCLATURE								PROJECT												
2040: Research, Development, Test & Evaluation, Army BA 5: Development & Demonstration (SDD)								PE 0604807A: Medical Materiel/Medical Biological Defense Equipment - Eng Dev								849: INFEC DIS DRUG/VACC ED												
	FY 2011				FY 2012				FY 2013				FY 2014				FY 2015				FY 2016				FY 2017			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
Dengue Tetravalent Vaccine (DTV) Critical Design Review (CDR)																												
DTV Phase 3 Adult Indication Studies																												
DTV Adult Indication Decision																												
DTV Milestone C (MS-C)																												
DTV Biologic Licensing Application (BLA) Submission																												
Malaria Prophylaxis Phase 3 Pivotal Clinical Trial																												
Malaria Prophylaxis (MS-C)																												
Paromomycin/Gentamicin Topical Antileishmanial Cream (TLC)																												
Paromomycin/Gentamicin TLC Phase 3 Clinical Trials																												
Paromomycin/Gentamicin TLC Milestone C (MS-C)																												
Paromomycin/Gentamicin TLC New Drug Application (NDA)																												
Paromomycin/Gentamicin TLC FDA Approval																												
Paromomycin/Gentamicin TLC																												
Leishmania Rapid Diagnostic Device MS-C																												
Leishmania Rapid Diagnostic Device FDA Approval																												
Leishmania Rapid Diagnostic Device Fielding/Delivery																												

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2013 Army			DATE: February 2012
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 5: <i>Development & Demonstration (SDD)</i>	R-1 ITEM NOMENCLATURE PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>	PROJECT 849: <i>INFEC DIS DRUG/VACC ED</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
Dengue Tetravalent Vaccine (DTV) Critical Design Review (CDR)	4	2011	4	2011
DTV Phase 3 Adult Indication Studies	2	2012	2	2015
DTV Adult Indication Decision	4	2013	4	2013
DTV Milestone C (MS-C)	4	2016	4	2016
DTV Biologic Licensing Application (BLA) Submission	4	2017	4	2017
Malaria Prophylaxis Phase 3 Pivotal Clinical Trial	4	2013	4	2015
Malaria Prophylaxis (MS-C)	1	2017	1	2017
Paromomycin/Gentamicin Topical Antileishmanial Cream (TLC)	1	2012	1	2014
Paromomycin/Gentamicin TLC Phase 3 Clinical Trials	3	2011	3	2013
Paromomycin/Gentamicin TLC Milestone C (MS-C)	1	2014	1	2014
Paromomycin/Gentamicin TLC New Drug Application (NDA)	4	2014	4	2014
Paromomycin/Gentamicin TLC FDA Approval	4	2015	4	2015
Paromomycin/Gentamicin TLC	1	2016	4	2017
Leishmania Rapid Diagnostic Device MS-C	1	2014	1	2014
Leishmania Rapid Diagnostic Device FDA Approval	2	2014	2	2014
Leishmania Rapid Diagnostic Device Fielding/Delivery	4	2014	4	2015

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2013 Army									DATE: February 2012		
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 5: <i>Development & Demonstration (SDD)</i>				R-1 ITEM NOMENCLATURE PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>				PROJECT VS8: <i>MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - END DEV</i>			
COST (\$ in Millions)	FY 2011	FY 2012	FY 2013 Base	FY 2013 OCO	FY 2013 Total	FY 2014	FY 2015	FY 2016	FY 2017	Cost To Complete	Total Cost
VS8: <i>MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - END DEV</i>	-	-	2.421	-	2.421	-	-	-	-	Continuing	Continuing
Quantity of RDT&E Articles											

A. Mission Description and Budget Item Justification

Funding for this project starts in FY 2013. Original models of Army Black Hawk MEDEVAC helicopters continue to play a major role in maintaining high US troop survival rates in Iraq and Afghanistan by evacuating wounded troops in less than one-hour. In 2009, a VCSA-approved force design update increased the number of air frames in the force from 12 to 15 aircraft for 37 MEDEVAC companies to better meet operational needs. In 2010, the Army Medical Department (AMEDD) accepted life-cycle management of the MEDEVAC MEP from PEO Aviation. In order to achieve required operational capability and enhance commonality across the MEDEVAC fleet, the MEDEVAC MEP program upgrades and retrofits the 256 MEDEVAC legacy helicopters to achieve the medical capability provided by the HH-60M, which is factory built for the MEDEVAC mission.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2011	FY 2012	FY 2013
Title: MEDEVAC Mission Sensor Forward Looking Infrared Radar (FLIR) Description: MEDEVAC Mission Sensor (MMS) FLIR for UH-60 aircraft. One of the requirements for the UH-60A/L MEDEVAC is a sensor system that will assist the pilots in locating patient pick-up points and assist them in maintaining situational awareness in night and adverse weather conditions. The MMS is currently being qualified for use on the HH-60M aircraft. This system will be installed on UH-60 aircraft using the proven Sponson-Mount FLIR system, which is currently being used in Operation Enduring Freedom (OEF) for the MEDEVAC mission. FY 2013 Plans: Will transition from VS7 and complete testing and integration of the Talon FLIR into the aircraft sponson to ensure maximum capability of the sensor, while minimizing impact to aircraft performance.	-	-	2.421
Accomplishments/Planned Programs Subtotals	-	-	2.421

C. Other Program Funding Summary (\$ in Millions)
N/A

D. Acquisition Strategy
Develop in-house or industrial prototypes in government-managed programs to meet military MEDEVAC and regulatory requirements for production and fielding.

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2013 Army		DATE: February 2012
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 5: <i>Development & Demonstration (SDD)</i>	R-1 ITEM NOMENCLATURE PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>	PROJECT VS8: <i>MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - END DEV</i>

E. Performance Metrics

Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2013 Army										DATE: February 2012			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 5: Development & Demonstration (SDD)				R-1 ITEM NOMENCLATURE PE 0604807A: Medical Materiel/Medical Biological Defense Equipment - Eng Dev				PROJECT VS8: MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - END DEV					
Product Development (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MEDEVAC Mission Sensor Forward Looking Infrared	TBD	Redstone Arsenal,AL	-	-		1.800		-		1.800	0.000	1.800	0.000
Subtotal			-	-		1.800		-		1.800	0.000	1.800	0.000
Support (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	SS/UCA	Redstone Arsenal:AL	-	-		0.621		-		0.621	0.000	0.621	0.000
Subtotal			-	-		0.621		-		0.621	0.000	0.621	0.000
			Total Prior Years Cost	FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals			-	-		2.421		-		2.421	0.000	2.421	0.000
Remarks													

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2013 Army

DATE: February 2012

APPROPRIATION/BUDGET ACTIVITY

2040: Research, Development, Test & Evaluation, Army
BA 5: Development & Demonstration (SDD)

R-1 ITEM NOMENCLATURE

PE 0604807A: Medical Materiel/Medical
Biological Defense Equipment - Eng Dev

	PROJECT
--	----------------

VS8: MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - END DEV

[illegible]

MEDEVAC Mission Sensor (MMS) FLIR	
-----------------------------------	--

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2013 Army			DATE: February 2012
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 5: <i>Development & Demonstration (SDD)</i>	R-1 ITEM NOMENCLATURE PE 0604807A: <i>Medical Materiel/Medical Biological Defense Equipment - Eng Dev</i>	PROJECT VS8: <i>MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - END DEV</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
MEDEVAC Mission Sensor (MMS) FLIR	4	2013	4	2013